the optical revolution in hypertension monitoring · presented at ieee international conference on...
TRANSCRIPT
1905 2018Cuffs are hard to get, hard to maintain, expensive and inconvenient.
The Cuff is a 100-Year-Old Solution, Little Progress
Attack the global hypertension epidemic by providinganytime/anywhere, inexpensive access to medical
grade blood pressure measurement and management
Our Mission
We use breakthrough optical sensing technology to enable ubiquitous, accurate and simple
measurement and data collection through smart device applications and other distributed
technologies
Our Mission
>30%Adult population affected
Hypertension is a global threat.It is both overlooked and under managed.
1.56BAdults living with
high blood pressure
Hypertension: The Silent Killing Disease
2xRisk of Premature
Death
3xRisk of Stroke and
Cardiovascular Disease
Introducing OptiBP
Our OptiBP smartphone application revolutionizes hypertension management by giving anybody the power to measure and monitor blood pressure with their smartphone.
© Biospectal. Proprietary and Confidential 7
Anytime, anywhere.
How Did We Get Here? The Velocity Form Model
© Biospectal. Proprietary and Confidential 8
OptiBPTM is the product of 10 years of research and development at the Swiss Center for Electronics and Microtechnology (CSEM) and 5 years of clinical validation at the CHUV hospital in Lausanne, Switzerland.
Extensive Development & Clinical Testing
CSEM has invested 10 years in platform R&D and Refinement
CHUV: Clinical studies since 2013
Prototype optical sensors used to test algorithms.
Biospectal’s Dr. Schoettker testing in the operating room against the arterial line BP standard.
How It Works: The Velocity Form Model (VFM)
Pulse Wave Velocity
OptiBP’s clinical grade, physiologically grounded computational model overcomes limitations in previous optical signal methods.
Pulse Wave Analysis
Veins
Arteries
Measurement of the velocityof the pressure wave
Measurement site #1
Measurement site #2
Measurement of the morphology of the pressure wave
Veins
Arteries
Measurement site
First, we capture periodic measurement of pulse wave velocity.
Second, we analyze the shape of the pressure wave to arrive at BP value output.
OptiBP has been clinically validated in first round validation comparing the smartphone against the blood pressure cuff and is already ISO 81060-2 compliant.
© Biospectal. Proprietary and Confidential
Successful Accuracy BenchmarkPresented at IEEE International Conference on Biomedical and
Health Informatics» Las Vegas, March 4-7 2018
Where are We Now?
We are Partnering with World Health Organization to validate & deploy OptiBP in multiple countries.
• Real world “stress testing” – large, diverse data set to tune our algorithm• WHO backing and reputation• Access to global financial resources
Validation Roadmap: Refinement & FDA
© Biospectal. Proprietary and Confidential 13
Q1 ’18 Q2 ‘18 Q3’18 Q4’ 18 Q1’ 19
FDA ISO 81060-2
100 patients inv. art.(Switzerland)
1200 patients (Tanzania, RSA, Bangladesh)
1000 patients(Switzerland)
FDA ISO 81060-3
We are conducting rigorous validation and data collection.
Where are We Going?
Provider Networks, Insurance, Pharma
WHO, OR studies,
Riva Digital Switzerland
Hypertensive/Health Forward Consumers
Global Health
Care Delivery System
Direct to Consumer
1VALIDATION
PHASE
MARKET ON RAMP
2PHASE
SCALE
3PHASE
2018 2019 2020
The Benefits of BP Monitor as Software
Instant global access
No extra hardware
Any time, anywhere availability
Dramatically improved user
experience
Connected, actionable
data
OptiBP is convenient, comfortable, and portable – with data that can be analyzed and shared easily with medical professionals.
Product Roadmap
Android
iOSAndroid+
Single UserPeriodic
AnalyticsCollaborationLifestyle/Mgmt
Extended Use CasesAdherenceScale
Population Insights
Web Portal
IoTData
Services/Analytics
Clinical On-Body
Professional MonitoringInpatient(OR)/Outpatient
ExtendedBiometrics
Expanded Biosensing
Consumer Wearables
2019 2020 2021 2022+
Competitive Environment
Competitors are either a hardware based variation on the cuff or not clinically accurate
© Biospectal. Proprietary and Confidential 18
Business Model
3
1
2
5
4
App sales: monthly subscription, tiered model
Upsell premium features & services: In product + web
3rd party licensing (IoT, White Label, Phone Mfgr)
Data monetization
Analytics services
© Biospectal. Proprietary and Confidential 19
Revenue Estimates
$341 658 $1 089 709 $2 219 842$3 782 043
$5 810 879$8 343 679
$11 420 761
$15 085 668
$19 385 426
$24 370 822
$30 096 708
$36 622 322
14 250
29 640
46 261
64 212
83 599
104 537
127 150
151 572
177 948
206 434
237 198
270 424
0
50 000
100 000
150 000
200 000
250 000
300 000
350 000
$0
$10 000 000
$20 000 000
$30 000 000
$40 000 000
$50 000 000
$60 000 000
$70 000 000
$80 000 000
janv 2019 févr 2019 mars 2019 avr 2019 mai 2019 juin 2019 juil 2019 août 2019 sept 2019 oct 2019 nov 2019 déc 2019
Annualized Subscribers and Revenue (U.S. Market @150M)
Annualized Net Recurring Subscription Revenue Monthly Subscribers Cumulative Net
$48M/yr.
U.S. Annualized Subscription Revenue in 12 months(EU= 30% of total)
• Free basic app (80%)• $9.99/mo premium
subscription (20%)
• TAM: 20%• SAM: 50% of TAM
• Penetration: 1.4%= 0.14% of total HTA market
Investment
$4.0M/12mo
© Biospectal. Proprietary and Confidential
Legal, Compliance, Certifications
$700
Tech Dev/Infrastructure
$1 400
BizDev/Mktg/PR
$200
Ops & Staffing
$1 400 Clinical Trial
Support
$300
Clinical
Trials $(2 000)
Milestones:Complete clinical trials Complete FDA/CE approvalDeliver shipping product (Android/iOS)Develop tech/data platformSecure U.S. + EU partnersBuild baseline team
Values in Thousands
Angel
$1.2MA ROUND
Our Team
Eliott Jones CEO
Digital health entrepreneurProduct innovatorYahoo, Logitech, Landor, Rambus, Harvard
Peter DolchCTO
25 year tech CEOStartup veteranEnterprise software, app & data systemsMIT
Thierry KunzCFO
Banking & Finance ExecutiveSerial entrepreneur
Prof. Patrick Schoettker CMO
Prof. Anesthesia & ER, CHUVSerial medtech inventor
[email protected] [email protected] [email protected] [email protected]